2.40
-0.25(-9.43%)
Currency In USD
Address
55 Park Lane
London, W1K 1NA
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 7495 2379
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
May 17, 2022
| Name | Title | Pay | Year Born |
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer & Executive Director | 588,000 | 1947 |
| Mr. Michael Paul Beck | Founder | 0 | 1957 |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer | 0 | 1959 |
| Ms. Keeren Shah | Chief Financial Officer | 0 | 1976 |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.